Last reviewed · How we verify
Peripheral arterial embolism — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Heparin Sodium In Plastic Container | HEPARIN | Merck & Co. | Anti-coagulant | Antithrombin-III | 1939-01-01 | |
| Heparin Sodium In Plastic Container | Heparin Sodium | Fresenius Kabi | Anticoagulant | Antithrombin III, Coagulation Factors Xa and IIa | 1939-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Fresenius Kabi · 1 drug in Peripheral arterial embolism
- Merck & Co. · 1 drug in Peripheral arterial embolism
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Peripheral arterial embolism:
- Peripheral arterial embolism treatment updates — RSS
- Peripheral arterial embolism treatment updates — Atom
- Peripheral arterial embolism treatment updates — JSON
Cite this brief
Drug Landscape (2026). Peripheral arterial embolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peripheral-arterial-embolism. Accessed 2026-06-10.
Related
- Peripheral arterial embolism full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing